Autoimmunity and the newer biopharmaceuticals

Fabiola Atzeni, Piercarlo Sarzi-Puttini

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients with rheumatoid arthritis (RA), Crohn's disease (CD) and spondyloarthritis (SpA) treated with selective tumor necrosis factor-alpha (TNFα) inhibitors may develop autoantibodies such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. According to the available safety data, 63.8% of CD patients and 49.1% of RA patients develop newly positive ANAs during infliximab treatment, and respectively 13 and 21.5% develop newly positive anti-dsDNA antibodies; the percentages are lower in patients treated with etanercept. We have recently reported that ANA and anti-dsDNA, but not anti-phospholipid (anti-aPL), antibodies can be induced by adalimumab, but to a lesser extent than other TNFα blocking agents. Interestingly, these autoantibodies have been only anecdotally associated with clinical manifestations suggesting drug-induced systemic lupus erythematosus (SLE). It was thought that the absence of such an association was related to the IgM or IgA isotypes of anti-dsDNA antibodies, as well as to low antibody affinity. Anti-phospholipid antibodies, which are mainly detectable by means of an anti-cardiolipin assay (aCL), have also been found in RA patients receiving TNF-blockers. In some cases, their appearance has been related to concomitant infectious processes but one paper suggests that they may predict a poor clinical outcome, no clear correlation has been found with the specific clinical manifestations of anti-aPL syndrome. There have also been reports on the development of anti-drug antibodies.

Original languageEnglish
Title of host publicationAutoantibodies
PublisherElsevier Inc.
Pages783-791
Number of pages9
ISBN (Print)9780444527639
DOIs
Publication statusPublished - 2007

Fingerprint

Autoimmunity
Antinuclear Antibodies
Antibodies
Anti-Idiotypic Antibodies
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Crohn Disease
Autoantibodies
Phospholipids
DNA
Cardiolipins
Antibody Affinity
Antiphospholipid Syndrome
Pharmaceutical Preparations
Systemic Lupus Erythematosus
Immunoglobulin M
Immunoglobulin A
Safety
Assays
Association reactions

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Atzeni, F., & Sarzi-Puttini, P. (2007). Autoimmunity and the newer biopharmaceuticals. In Autoantibodies (pp. 783-791). Elsevier Inc.. https://doi.org/10.1016/B978-044452763-9/50100-1

Autoimmunity and the newer biopharmaceuticals. / Atzeni, Fabiola; Sarzi-Puttini, Piercarlo.

Autoantibodies. Elsevier Inc., 2007. p. 783-791.

Research output: Chapter in Book/Report/Conference proceedingChapter

Atzeni, F & Sarzi-Puttini, P 2007, Autoimmunity and the newer biopharmaceuticals. in Autoantibodies. Elsevier Inc., pp. 783-791. https://doi.org/10.1016/B978-044452763-9/50100-1
Atzeni F, Sarzi-Puttini P. Autoimmunity and the newer biopharmaceuticals. In Autoantibodies. Elsevier Inc. 2007. p. 783-791 https://doi.org/10.1016/B978-044452763-9/50100-1
Atzeni, Fabiola ; Sarzi-Puttini, Piercarlo. / Autoimmunity and the newer biopharmaceuticals. Autoantibodies. Elsevier Inc., 2007. pp. 783-791
@inbook{0b307ef1c79449bc8b9500bd19ce2173,
title = "Autoimmunity and the newer biopharmaceuticals",
abstract = "Patients with rheumatoid arthritis (RA), Crohn's disease (CD) and spondyloarthritis (SpA) treated with selective tumor necrosis factor-alpha (TNFα) inhibitors may develop autoantibodies such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. According to the available safety data, 63.8{\%} of CD patients and 49.1{\%} of RA patients develop newly positive ANAs during infliximab treatment, and respectively 13 and 21.5{\%} develop newly positive anti-dsDNA antibodies; the percentages are lower in patients treated with etanercept. We have recently reported that ANA and anti-dsDNA, but not anti-phospholipid (anti-aPL), antibodies can be induced by adalimumab, but to a lesser extent than other TNFα blocking agents. Interestingly, these autoantibodies have been only anecdotally associated with clinical manifestations suggesting drug-induced systemic lupus erythematosus (SLE). It was thought that the absence of such an association was related to the IgM or IgA isotypes of anti-dsDNA antibodies, as well as to low antibody affinity. Anti-phospholipid antibodies, which are mainly detectable by means of an anti-cardiolipin assay (aCL), have also been found in RA patients receiving TNF-blockers. In some cases, their appearance has been related to concomitant infectious processes but one paper suggests that they may predict a poor clinical outcome, no clear correlation has been found with the specific clinical manifestations of anti-aPL syndrome. There have also been reports on the development of anti-drug antibodies.",
author = "Fabiola Atzeni and Piercarlo Sarzi-Puttini",
year = "2007",
doi = "10.1016/B978-044452763-9/50100-1",
language = "English",
isbn = "9780444527639",
pages = "783--791",
booktitle = "Autoantibodies",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Autoimmunity and the newer biopharmaceuticals

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

PY - 2007

Y1 - 2007

N2 - Patients with rheumatoid arthritis (RA), Crohn's disease (CD) and spondyloarthritis (SpA) treated with selective tumor necrosis factor-alpha (TNFα) inhibitors may develop autoantibodies such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. According to the available safety data, 63.8% of CD patients and 49.1% of RA patients develop newly positive ANAs during infliximab treatment, and respectively 13 and 21.5% develop newly positive anti-dsDNA antibodies; the percentages are lower in patients treated with etanercept. We have recently reported that ANA and anti-dsDNA, but not anti-phospholipid (anti-aPL), antibodies can be induced by adalimumab, but to a lesser extent than other TNFα blocking agents. Interestingly, these autoantibodies have been only anecdotally associated with clinical manifestations suggesting drug-induced systemic lupus erythematosus (SLE). It was thought that the absence of such an association was related to the IgM or IgA isotypes of anti-dsDNA antibodies, as well as to low antibody affinity. Anti-phospholipid antibodies, which are mainly detectable by means of an anti-cardiolipin assay (aCL), have also been found in RA patients receiving TNF-blockers. In some cases, their appearance has been related to concomitant infectious processes but one paper suggests that they may predict a poor clinical outcome, no clear correlation has been found with the specific clinical manifestations of anti-aPL syndrome. There have also been reports on the development of anti-drug antibodies.

AB - Patients with rheumatoid arthritis (RA), Crohn's disease (CD) and spondyloarthritis (SpA) treated with selective tumor necrosis factor-alpha (TNFα) inhibitors may develop autoantibodies such as antinuclear antibodies (ANAs) and anti-double-stranded DNA (anti-dsDNA) antibodies. According to the available safety data, 63.8% of CD patients and 49.1% of RA patients develop newly positive ANAs during infliximab treatment, and respectively 13 and 21.5% develop newly positive anti-dsDNA antibodies; the percentages are lower in patients treated with etanercept. We have recently reported that ANA and anti-dsDNA, but not anti-phospholipid (anti-aPL), antibodies can be induced by adalimumab, but to a lesser extent than other TNFα blocking agents. Interestingly, these autoantibodies have been only anecdotally associated with clinical manifestations suggesting drug-induced systemic lupus erythematosus (SLE). It was thought that the absence of such an association was related to the IgM or IgA isotypes of anti-dsDNA antibodies, as well as to low antibody affinity. Anti-phospholipid antibodies, which are mainly detectable by means of an anti-cardiolipin assay (aCL), have also been found in RA patients receiving TNF-blockers. In some cases, their appearance has been related to concomitant infectious processes but one paper suggests that they may predict a poor clinical outcome, no clear correlation has been found with the specific clinical manifestations of anti-aPL syndrome. There have also been reports on the development of anti-drug antibodies.

UR - http://www.scopus.com/inward/record.url?scp=84882559410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882559410&partnerID=8YFLogxK

U2 - 10.1016/B978-044452763-9/50100-1

DO - 10.1016/B978-044452763-9/50100-1

M3 - Chapter

AN - SCOPUS:84882559410

SN - 9780444527639

SP - 783

EP - 791

BT - Autoantibodies

PB - Elsevier Inc.

ER -